NR-19347_麻风分枝杆菌,ND-O-HSA(基于PGL-I的人血清白蛋白糖缀合物)(抗原制剂）

NR-19347??Mycobacterium leprae, ND-O-HSA (PGL-I-based Glycoconjugate of Human Serum Albumin)(Antigen Preparations)|Mycobacterium leprae|ND-O-HSA (PGL-I-based Glycoconjugate of Human Serum Albumin)|Room temperature (Note: Reconstituted material should be aliquoted and stored frozen at -20°C or colder.)|BEI Resources or NIH - Leprosy Research Support ContractAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium leprae, ND-O-HSA (PGL-I-based Glycoconjugate of Human Serum Albumin), NR-19347.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-19347 was made using the serologically active terminal disaccharide (ND; natural disaccharide) portion of phenolic glycolipid-I (PGL-I) linked to human serum albumin (HSA) via an octyl linker arm. PGL-I is unique to Mycobacterium leprae (M. leprae) where it is produced in copious amounts. It plays a role in invasion of human nerves by binding to the receptors on the Schwann cells. PGL-I causes a specific antibody to be produced in the sera of leprosy patients. Each vial contains approximately 250 ?g of lyophilized ND-O-HSA from M. leprae. Note: NR-19347 can be reconstituted in sterile phosphate buffered saline, pH 7.2, or another suitable buffer.